Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Breast Neoplasms 25Neoplasm Metastasis 5Neoplasms 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2HER2-positive Breast Cancer 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Preference 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1Inflammatory Breast Neoplasms 1

Interventions

Radiosurgery 51Magnetic Resonance Spectroscopy 34Temozolomide 28pembrolizumab 24Bevacizumab 24Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10Blood Specimen Collection 9trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5Lomustine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Brain Neoplasms × Ado-Trastuzumab Emtansine × 1 year × Clear all
NCT05593094 2026-05-26

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Hoffmann-La Roche

Phase 1/2 Active not recruiting
210 enrolled
CNS

Brain Neoplasms

NCT05323955 2026-03-17

BRIDGET

Duke University

Phase 2 Active not recruiting
48 enrolled
CNS

Brain Neoplasms

NCT05673928 2026-01-21

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡